louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01088269: Blood Pressure Assessment in Atrial Fibrillation
Official title: Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Keywords: Blood Pressure Measurement
Atrial Fibrillation
Blood pressure measurement in atrial fibrillation
Atrial Fibrillation diagnosis
Lead sponsor: University of Athens
Sponsor class: OTHER
First posted: 2010-03-17
Enrollment: 100
Sex: ALL
Minimum age (years): 25
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: SUBJECTS REFERRED TO HYPERTENSION CENTER

Brief summary: This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

* clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)
* 24-hour ambulatory blood pressure monitoring
* determination of various serum markers and cardiac ultrasound.
* evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG


Eligibility criteria: Inclusion Criteria:

* Hypertensives adults in atrial fibrillation

Exclusion Criteria:

* Renal disease (Cr \> 2 mg/l).
* Patients with pacemaker rhythm during the study.
* Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.

Primary outcomes:
measure: Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Hypertension Center, Third Internal Medicine Dpt, University of Athens
Study officials:
affiliation: Hypertension Center,Third Department of Medicine,University of Athens,Greece
name: George S Stergiou, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04104269: Mechanical Structure Complications After Acute Myocardial Infarction
Official title: Comparative Risk Factors of Mechanical Structure Complications After Acute Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myocardial Infarction
Keywords: Heart rupture
Acute myocardial infarction
Lead sponsor: Xiamen Cardiovascular Hospital, Xiamen University
Sponsor class: OTHER
First posted: 2019-09-26
Enrollment: 35621
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population of acute myocardial infarction (STEMI or NSTEMI) patients.

Brief summary: To determine the incidence and factors associated with heart rupture (HR) in acute myocardial infarction patients.

Detailed description: We compared characteristics and angiographic patterns of heart rupture and without heart rupture patients enrolled in the trial.

Eligibility criteria: Inclusion Criteria:

1. Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)

Exclusion Criteria:

1. Non-cardiovascular comorbidity for AMI

Primary outcomes:
measure: Heart rupture
timeFrame: Mortality 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Xiamen
country: China
facility: Xiamen Cardiovascular Hospital Xiamen University
state: Fujian
Study officials:
affiliation: Xiamen Cardiovascular Hospital, Xiamen University
name: Yan Wang, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT03577769: Nosocomial Bacteriuria in Geriatric Internal Medicine Services and Follow-up Care and Geriatric Rehabilitation of the Strasbourg University Hospitals
Official title: Health Care-associated Bacteriuria in Geriatric Wards in Strasbourg's University Hospital : a Comparative Study of Bacterial Ecology Between 2003, 2007 and 2017
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urinary Tract Infection
Keywords: Health care associated urinary tract infection
Bacteriuria
Elderly
Geriatrics
Antimicrobial resistance
Multi-resistant bacteria
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2018-07-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * patient of age who has been hospitalized in geriatric wards (rehabilitation car service and internal medicine) of Strasbourg's University hospital
* date of hospital leaving after 1/1/17 and before 1/1/18
* patient who has a health-care urinary tract infection (occurred more than 48h after admission)

Brief summary: This thesis is a comparative study of the epidemiological characteristics of health-care associated bacteriuria in short and medium term of geriatrics wards in Strasbourg's University Hospital, between 2003 and 2017, in the follow-up of Eric de Pasquale's thesis in 2010.

This comparative study will allow to see the evolution of urinary bacterial ecology, bacterial sensitivity to antibiotics, and the part of multi-resistant bacteria, during these 14 years in geriatric services in Strasbourg.


Eligibility criteria: Inclusion Criteria:

* patient of age who has been hospitalized in geriatric wards (rehabilitation car service and internal medicine) of Strasbourg's University hospital
* date of hospital leaving after 1/1/17 and before 1/1/18
* patient who has a health-care urinary tract infection (occurred more than 48h after admission)
* single bacteria in the CBEU
* bacteriuria \> 105 cfu/mL regardless which clinical context or bacteria
* if a patient has several bacteriuria, they can be included if they appear after a precedent episode well treated or if the bacteria is different from the precedent

Exclusion Criteria:

* participation refusal
* Leaving of hospital out of the inclusion period
* Urinary tract infection which occurred less than 48h after admission (communitarian infection)
* bacteriuria \< 105 cfu/mL
* multiple bacteria in the CBEU

Primary outcomes:
measure: Bacterial sensitivity (antibiotic resistance testing)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service Geriatrie - Soins de Suite Et Readaptation
Study officials:
References:
Clinical trial NCT01759069: RCT: Effectiveness of a Microscope During Dental Root Apical Surgery
Official title: The Effectiveness of a Microscope During Apical Surgery; a Prospective Randomized Controlled Clinical Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Effectiveness of Microscope During Apical Surgery in Endodontic Treated Teeth.
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
First posted: 2013-01-02
Enrollment: 190
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: An endodontic treatment is the standard therapy for teeth with periapical periodontitis. The overall success rate for this treatment is high; 97% of the treated teeth are retained in the oral cavity after 8 years (Salehrabi \& Rotstein, 2004). However, there are teeth that have a persistent granuloma because of various reasons and need endodontic retreatment or apical surgery. Overall results in literature for an endodontic retreatment show a success rate of 77%-89% (Ng, Mann, \& Gulabivala, 2008; Salehrabi \& Rotstein, 2010), the results of apical surgery are more or less similar (von Arx, 2005). Which of the two methods is preferred for failed root canal treatments is dependant on a variety of reasons. (For example an amount of gutta-percha outside the apex of the root is better corrected by apical surgery. Persistent infection as a result of insufficient gutta-percha amounts in a treated root is best treated with an endodontic retreatment.) The overall results in apical surgery have increased the past years due to better preparation of the apical end of the root by the use of an ultrasonic device (de Lange, Putters, Baas, \& van Ingen, 2007) and new materials that are used for filling of the rootend e.g. MTA (von Arx, Hanni, \& Jensen, 2010)

Objective of the study:

The objective of this study is to assess whether or not apical surgery that is carried out with the help of a microscope has a higher success rate than apical surgery without the use of a microscope. No RCT is found in present literature (Del Fabbro, Taschieri, Lodi, Banfi, \& Weinstein, 2009).


Eligibility criteria: Inclusion Criteria:

* Peri-apical lesion on one of the teeth, confirmed on radiograph.
* Previous endodontic treatment was more than 6 months earlier.

Exclusion Criteria:

* Root fracture.
* Periodontal origin of apical infection or absence of marginal buccal bone after flap elevation.
* Root perforation.
* No previous endodontic treatment.
* Previous endodontic surgery.

Primary outcomes:
measure: Success is measured by Clinical outcome and radiographic assessment.
timeFrame: 6 months and 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Academic Medical Center; Clinic of Oral and Maxillofacial Surgery
Study officials:
References:
Clinical trial NCT02190669: Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control
Official title: Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 1 Diabetes
Type 2 Diabetes
Lead sponsor: Sansum Diabetes Research Institute
Sponsor class: OTHER
First posted: 2014-07-15
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: individuals without diabetes and those with type 1 and type 2 diabetes

Brief summary: This proposal seeks to gather continuous blood glucose and physical activity data from individuals with and without diabetes.

Detailed description: This proposal seeks to gather continuous blood glucose and physical activity data from individuals with and without diabetes who are physically active and exercising for health benefits. The investigators hypothesize that insulin requirements will be inversely related to intensity of activity and an algorithm will be able to detect physical activity and automatically adjust insulin doses. Once such an algorithm has been determined for an individual, it can be applied to future similar situations, but ideally the algorithm will be dynamically refined based on closed-loop feedback information.

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria for subjects with diabetes
* Type 1 diabetes or insulin requiring type 2 diabetes for at least 1 year
* Use insulin to control diabetes
* Physically active (regularly work out, swim, run, walk, bike, etc.)
* Free of major micro- and macrovascular complications of diabetes
* 18-75 years of age
* A1C \< 9.0% Inclusion criteria for subjects without diabetes
* No evidence of diabetes and physically active

Exclusion Criteria:

* unwilling to perform repeated glucose checks or take insulin as instructed
* abnormal thyroid function, kidney function, liver function
* pregnancy

Primary outcomes:
measure: Document the glycemic response of individuals without diabetes and with type 1 or type 2 diabetes
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Barbara
country: United States
facility: Sansum Diabetes Research Institute
state: California
Study officials:
affiliation: Sansum Diabetes Research Institute
name: Kristin Castorino, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04243369: Collaboration Live
Official title: Collaboration Live Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy Related
Keywords: Collaboration Live
Telemedicine
Ultrasound
Lead sponsor: Philips Clinical & Medical Affairs Global
Sponsor class: INDUSTRY
First posted: 2020-01-28
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Collaboration Live is a prospective, single-arm clinical study of subjects who provide written consent. Subjects are scanned using a Philips EPIQ 5 or EPIQ 7 Ultrasound System equipped with Collaboration Live software. The study investigator will evaluate performance of the Collaboration Live tool with regard to performance of conferencing, sharing and control capabilities. Adverse events will be reported and the study investigator will assess potential relationship to the study device or study procedure. Additionally, the utility of Collaboration Live in remote consult of study patients will be evaluated. No patient follow-up beyond the initial consultation will be conducted with the Collaboration Live software solution.


Eligibility criteria: Inclusion Criteria:

* Subject is at least 18 years of age
* Subject in indicated for a routine Obstetrics/Gynecology ultrasound examination at the site.
* Subject is willing and capable of providing informed consent and participating in this study

Exclusion Criteria:

* A medical condition or co-morbidity that would be unduly affected by study participation, per investigator discretion

Primary outcomes:
measure: Rate of Clinically Acceptable Performance of Remote Control Functionality
timeFrame: Intra-procedural (1 day)
Secondary outcomes:
measure: Number of Participants With Technical Issues
timeFrame: Intra-procedural (1 day)
measure: Success Rates for Key Tasks in the Collaborative Exam
timeFrame: Intra-procedural (1 day)
measure: Travel Reduction Attributable to Use of Collaboration Live
timeFrame: Intra-procedural (1 day)
measure: Ease of Use
timeFrame: Intra-procedural (1 day)
measure: User Feedback Regarding Streaming, Image Quality and Overall Experience
timeFrame: Intra-procedural (1 day)
measure: Patient Feedback Regarding Remote Consultation
timeFrame: 1 day
measure: Impact of Remote Consultation on Reimbursement
timeFrame: 30 days
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: Perinatal Associates of New Mexico
state: New Mexico
city: Rio Rancho
country: United States
facility: Perinatal Associates of New Mexico
state: New Mexico
city: Santa Fe
country: United States
facility: Perinatal Associates of New Mexico
state: New Mexico
Study officials:
References:
Clinical trial NCT04628169: Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum
Official title: Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pathophysiology of Placenta Accreta
Keywords: Netrin-1, neogenin,PAS, zeb-1
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-11-13
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 PAS specimens and 30 placental specimens from matched control.

Brief summary: The main goal of this study is to assess the role of Netrin 1, neogenin and ZEB1 in PAS-associated invasion

Detailed description: * To evaluate the immunohistochemical expression of these proteins in PAS specimens in comparison with the control placental tissues.
* To correlate their expression with the demographic parameters.
* To assess the correlation between their expression in PAS specimens.

Eligibility criteria: inclusion criteria

* PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS

exclusion criteria

* patients with fundal and middle anterior or posterior placenta,
* pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
* uterine scar pregnancies were excluded

Primary outcomes:
measure: impact of netrin-1 in the pathophysiology of placenta accreta spectrum
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Hanaa Mohammed Mohammed Sayed
Study officials:
References:
Clinical trial NCT06897969: Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment
Official title: Comparison of Intralesional Triamcinolone and Intralesional Verapamil in the Treatment of Keloids
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Keloid Scars
Keywords: Keloid
Vancouver scar scale
Triamcinolone
Verapamil
Intralesional injection
Lead sponsor: Nishtar Medical University
Sponsor class: OTHER
First posted: 2025-03-27
Enrollment: 60
Sex: ALL
Minimum age (years): 10
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.


Eligibility criteria: Inclusion Criteria:

* size of keloid1-5 cm,
* on any site of the body,
* duration less then five years and
* baseline Vancouver scar score of more the or equal to 5

Exclusion Criteria:

* Pregnant or lactating women,
* family history of keloids,
* acromegaly, and
* congestive cardiac diseases

Primary outcomes:
measure: Change in Vancouver Scar Score
timeFrame: Vancouver Scar score will be measured at baseline (before treatment assignment) and then 4-weeks after completion of treatment - 16-weeks after randomization.
Secondary outcomes:
Other outcomes:
Locations:
city: Multan
country: Pakistan
facility: Nishtar Medical University & Hospital
state: Punjab
Study officials:
affiliation: Nishtar Medical University
name: Dr. Aliya Akhtar, FCPS
role: STUDY_DIRECTOR
References:
citation: Kuang J, An P, Li W. Comparative efficacy and safety of verapamil and triamcinolone in keloid and hypertrophic scar treatment: a meta-analysis. J Cosmet Laser Ther. 2021 Feb 17;23(1-2):26-34. doi: 10.1080/14764172.2021.1950765. Epub 2021 Jul 18.
citation: Uzair M, Butt G, Khurshid K, Pal SS. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.
citation: Saki N, Mokhtari R, Nozari F. Comparing the Efficacy of Intralesional Triamcinolone Acetonide With Verapamil in Treatment of Keloids: A Randomized Controlled Trial. Dermatol Pract Concept. 2019 Jan 31;9(1):4-9. doi: 10.5826/dpc.0901a02. eCollection 2019 Jan.
Clinical trial NCT00018369: Age-Related Changes in Stress Hormone Regulation
Official title: Mechanism of Aging-Related Changes in (HPA) Hydrocortisone Corticotropin Feedback Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physiological Processes
Aging
Keywords: Aging
Hydrocortisone Corticotropin Feedback
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: Studies investigating physiological processes involved in aging-related deficits in regulation of stress hormone systems.


Eligibility criteria: Exclusion Criteria:

* History of major psychiatric disorders,
* Neurologic disorder affecting cognitive function,
* Unstable medical problems,
* Medications including antidepressants, neuroleptics, anxiolytics, CNS stimulants, narcotic analgesics, anti-convulsants,
* Drugs effecting HPA axis function,
* Vision and hearing deficits,
* Undergoing major life event within one month or
* Loss of family member within 6 months.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: VA Puget Sound Health Care System
state: Washington
Study officials:
name: Richard Dorin
name: Elaine Peskind
name: Alan Schatzberg
name: Joseph Belanoff
References:
Clinical trial NCT01681069: Efficacy and Safety of IQP-VV-102 in Weight Management
Official title: Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-VV-102 in Reducing Body Weight in Overweight and Obese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Obesity
Overweight
Lead sponsor: InQpharm Group
Sponsor class: INDUSTRY
First posted: 2012-09-07
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored


Eligibility criteria: Inclusion Criteria:

* Age 18 to 60 years
* 25 kg/m2 ≤ BMI ≤ 35 kg/m2
* Written informed consent

Exclusion Criteria:

* Known sensitivity to sources of the active ingredients and excipients
* Pregnancy or nursing
* Inability to comply with study requirements, e.g. due to language difficulties
* Participation in another study during the last 30 days of the screening visit

Primary outcomes:
measure: Change in Body Weight at End of Study Compared to Baseline
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in Waist Circumference (in cm) at End of Study From Baseline
timeFrame: 12 weeks
measure: Change in Mean Body Fat at End of Study From Baseline
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Barbara Grube
Study officials:
affiliation: Practice for General Medicine
name: Barbara Grube, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Grube B, Bongartz U, Alt F. IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety. Evid Based Complement Alternat Med. 2015;2015:413075. doi: 10.1155/2015/413075. Epub 2015 May 17.